Deepika Jalota's Insider Trades & SAST Disclosures
Deepika Jalota's most recent trade in PMV Pharmaceuticals Inc was a trade of 300,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Deepika Jalota.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PMV Pharmaceuticals Inc | Deepika Jalota | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 300,000 | 300,000 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Deepika Jalota | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.50 per share. | 11 Sep 2024 | 7,218 | 118,283 | - | 1.5 | 10,853 | Common Stock |
| PMV Pharmaceuticals Inc | Deepika Jalota | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Aug 2024 | 125,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Deepika Jalota | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Deepika Jalota | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 90,774 | 90,774 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Deepika Jalota | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Aug 2024 | 68,100 | 0 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Deepika Jalota | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Aug 2024 | 22,674 | 0 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Jalota Deepika | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 225,095 | 225,095 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Jalota Deepika | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 95,555 | 125,501 | - | 0 | Common Stock | |
| PMV Pharmaceuticals Inc | Deepika Jalota | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 125,000 | 125,000 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Deepika Jalota | SVP, Regulatory Affairs and QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2022 | 34,050 | 34,050 | - | 0 | Common Stock | |
| PMV Pharmaceuticals Inc | Deepika Jalota | SVP, Regulatory Affairs and QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 68,100 | 68,100 | - | - | Employee Stock Option (right to buy) | |
| PMV Pharmaceuticals Inc | Deepika Jalota | SVP, Regulatory Affairs and QA | Sale of securities on an exchange or to another person at price $ 33.78 per share. | 17 Aug 2021 | 2,896 | 0 | - | 33.8 | 97,814 | Common Stock |
| PMV Pharmaceuticals Inc | Deepika Jalota | SVP, Regulatory Affairs and QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2021 | 2,896 | 87,320 | - | - | Stock option (right to buy) | |
| PMV Pharmaceuticals Inc | Deepika Jalota | SVP, Regulatory Affairs and QA | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.53 per share. | 17 Aug 2021 | 2,896 | 2,896 | - | 3.5 | 10,223 | Common Stock |
| PMV Pharmaceuticals Inc | Deepika Jalota | SVP, Regulatory Affairs and QA | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 22,674 | 22,674 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges